oral SAM-competitive PRMT5 inhibitor

Ph. I candidate for solid tumors (adv. or met.)

SBDD utilizing PRMT5:MEP50 w/ A9145C

Molecular Cancer Therapy

Pfizer Oncology

10.   The Pfizer SAM-competitive PRMT5 inhibitor, PF-06939999 is a Ph. I clinical candidate in dose escalation in solid tumors. Ph. I data has been reported showing signs of early efficacy with cytopenias as…


 become a member to continue reading

Ask your company or librarian about a Drug Hunter membership to to see all summaries and get access to even more helpful information.

  • Stay up-to-date and save more time with exclusive members-only content
  • On-board new team members with educational content and case studies
  • Generate ideas and discussion with easy-to-read slide decks
  • Generate ideas and discussion with easy-to-read slide decks